Opus Genetics (IRD) director awarded 24,367 restricted stock units, now holds 317,318 shares

Rhea-AI Filing Summary

MANUSO JAMES S J reported acquisition or exercise transactions in this Form 4 filing.

Opus Genetics, Inc. director JAMES S J MANUSO received a grant of 24,367 shares of Common Stock in the form of restricted stock units at a stated price of $0.00 per share. Following this award, he holds 317,318 shares directly. The RSUs vest upon the earlier of one year from the grant date or the day before the company’s next annual meeting of stockholders, provided he continues in service through the vesting date.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider MANUSO JAMES S J

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	24,367	$0.00	--

Holdings After Transaction: Common Stock — 317,318 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

RSU grant size: 24,367 shares Post-transaction holdings: 317,318 shares Grant price per share: $0.00 per share +1 more

4 metrics

RSU grant size 24,367 shares Restricted stock units granted on April 20, 2026

Post-transaction holdings 317,318 shares Total Common Stock directly held after grant

Grant price per share $0.00 per share Stated price for RSU award

Vesting period 1 year or until next annual meeting RSUs vest on earlier of one-year anniversary or day prior to next annual meeting

Key Terms

restricted stock units, annual meeting of stockholders, grant, award, or other acquisition

3 terms

restricted stock units financial

"Represents a grant of restricted stock units which vest upon the earlier"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

annual meeting of stockholders financial

"the day prior to the Issuer's next annual meeting of stockholders"

grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MANUSO JAMES S J

(Last) (First) (Middle)

C/O OPUS GENETICS, INC.

8 DAVIS DRIVE, SUITE 220

(Street)

DURHAM NORTH CAROLINA 27713

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Opus Genetics, Inc. [ IRD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/20/2026		A		24,367(1)	A	$0	317,318	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a grant of restricted stock units which vest upon the earlier of the one (1) year anniversary of the grant date or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, subject to the Reporting Person's continuing service through the vesting date.

	/s/ Amy Rabourn, by Power of Attorney	04/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Opus Genetics (IRD) report for JAMES S J MANUSO?

Opus Genetics reported that director JAMES S J MANUSO received 24,367 shares of Common Stock as a grant of restricted stock units. The award was recorded at a price of $0.00 per share and increases his directly held position to 317,318 shares after the transaction.

How many Opus Genetics (IRD) shares does JAMES S J MANUSO hold after this Form 4?

After the reported grant, director JAMES S J MANUSO directly holds 317,318 shares of Opus Genetics Common Stock. This total includes the 24,367 restricted stock units awarded in the transaction, which are subject to vesting conditions based on time and the next annual stockholder meeting.

What are the vesting terms of the restricted stock units granted to the Opus Genetics director?

The restricted stock units vest on the earlier of one year after the grant date or the day before Opus Genetics’ next annual meeting of stockholders. Vesting is conditioned on the reporting person’s continued service with the company through the applicable vesting date described in the footnote.

Was the Opus Genetics (IRD) director’s Form 4 transaction a market purchase or sale?

The Form 4 shows a grant categorized as a “grant, award, or other acquisition,” not a market trade. The 24,367 shares of Common Stock were received as restricted stock units at a stated price of $0.00 per share rather than through an open-market purchase or sale.

Is the Opus Genetics (IRD) Form 4 transaction direct or indirect ownership?

The filing classifies the director’s holdings as direct ownership. The 24,367 restricted stock units and the resulting 317,318 total shares following the transaction are reported with a direct ownership code, meaning they are held directly rather than through an intermediary entity or trust.